SkyCell

PharmaLifeScience News

...

Andrew Witty steps down as UnitedHealth CEO
Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced by Stephen Hemsley, chair of UnitedHealth’s board.
READ MORE
...

Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and diabetes drugs.
READ MORE
...

Health equity can be a competitive advantage: What pharma leaders need to know
Health equity can be a competitive advantage: What pharma leaders need to knowNicole.RaleighWed, 07/05/2025 - 16:00Bookmark thisNicole.RaleighWed, 07/05/2025 - 16:00Bookmark this
READ MORE

Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly

Sanofi and CD&R finalise Opella deal, launching global consumer healthcare giant

Trilobio raises $8 M to deliver whole lab automation for biologists

Carbon Insertion Technique Opens New Chemical Space for Medicines

Belfast’s Amply raises $1.75m for AI drug discovery

AAX Biotech enters collaboration for high-resolution epitope mapping

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Bristol Myers Squibb announces $40bn US investment plan over five years

SETU to advance ocular disease research with €3.1m funding

GSK buys Boston Pharmaceutical’s new liver disease drug for up to $2bn

Solgate Streamlines SLC Drug Discovery with INTEGRA’s Automated Pipetting Systems

World-first approval supports AstraZeneca’s sustainability goals

Scientists Use AI to Predict Future Viruses and Design Better Vaccines

Roche plans $700m manufacturing plant in the US

Trump vows to lower drug prices in the US by up to 80%

LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment

AI-powered drug discovery is outpacing regulators, with Eric Luellen

Scientists enhance T cell immunity for more durable vaccines

Optimizing Clinical Trials with Precision Medicine: A Candid Expert Discussion

Bluebird extends deal deadline; Affimed files for insolvency

Clinigen announces executive appointments to drive growth and investor value
Ellab